Institute for Psychiatry, Psychology, & Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.
Mol Autism. 2020 May 24;11(1):37. doi: 10.1186/s13229-020-00348-z.
A number of clinical trials of cell therapies for autism spectrum disorder have been conducted, and some have published their outcomes. This review considers the data that have emerged from this small set of published trials, evaluates their success, and proposes further steps that could be taken if this field of endeavour is to be pursued further. A number of reservations arise from this tranche of studies, specifically the absence of identified therapeutic targets, and deficiencies in the therapeutic approach that is being employed. If this therapeutic direction is to be pursued further, then additional pre-clinical studies are recommended that might lead to improvements in patient stratification, biomarkers, the defined mode of action, and the preparation and identification of the therapeutic cells themselves.
已经进行了许多自闭症谱系障碍细胞疗法的临床试验，其中一些已经公布了结果。本综述考虑了这一小部分已发表试验所产生的数据，评估了它们的成功，并提出了如果进一步开展这一领域的工作可以采取的进一步步骤。这些研究存在一些保留意见，特别是缺乏明确的治疗靶点，以及所采用的治疗方法存在缺陷。如果要进一步探索这一治疗方向，建议进行额外的临床前研究，这可能会改善患者分层、生物标志物、明确的作用模式以及治疗细胞的制备和鉴定。
